Navigation Links
Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients

ells affected by Parkinson's disease, as well as an excellent safety profile over a wide range of CERE-120 dose levels."

About Phase 2 Trial of CERE-120 Currently Underway

A double-blind, controlled Phase 2 clinical trial is now enrolling 51 patients with advanced Parkinson's disease at nine medical centers in the United States, with two thirds of patients being enrolled in the active treatment group and one third in the control group. Patients are receiving CERE-120 via stereotactic neurosurgery to deliver the drug into the putamen region of the brain. Patients will be followed for 12 months for safety and efficacy. Contacts at the medical centers involved in this study can be found through a link on the Ceregene web site: www.ceregene.com.

About CERE-120

CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin (NTN), a naturally occurring protein known to repair damaged and dying dopamine-secreting neurons, keeping them alive and functioning normally. NTN is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharmacological properties, and both have been shown to benefit the midbrain dopamine neurons that degenerate in Parkinson's disease and are responsible for the major motor impairments. CERE-120 is delivered by stereotactic injection to the affected area of the brain, providing stable, long-lasting expression of NTN in a highly targeted fashion. Ceregene owns exclusive technology and product rights to CERE-120.

About Parkinson's disease

Parkinson's disease is a progressive movement disorder that affects at least one million people in the United States. It is caused by a reduction in dopamine containing nerve cells of the midbrain. Dopamine is a neurotransmitter involved in controlling movement and coordination, so Parkinson's patients experiencing a reduction of
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Post Your Comments:
(Date:11/30/2009)...wire/ -- StemCyte, Inc. concluded an exclusive lic... Sinica, the National Laboratory of Taiwan, for ce...y (IP) related to the treatment of Chronic Stroke ... by a team led by Professor John Lin, MD, PhD and ...ently the exclusive collaborator with StemCyte on ...
(Date:11/30/2009)... eHealthSource.com launched the fir...roducts approved for Flexible Spending Account or ... is also the first to exclusively carry value-bran...p to 75 percent on everyday healthcare needs. ,... headaches - high costs and complexity," says eHea...
(Date:11/30/2009)... Health Robotics today announced,it...nd product specifications,for a new and revolution...on", a new key component of its i.v. Room of the F...ooth # 114). , "I look forward to see the...lueprints and to find out if TPNstation appears to...
Breaking Medicine Technology:StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke 2StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke 3eHealthSource.com Launches Online Shopping Site Dedicated to Over-the Counter Medications Approved for FSA/HSA Claims 2Health Robotics to Unveil TPNstation(TM) at the American Society of Health-System Pharmacists on December 7th 2Health Robotics to Unveil TPNstation(TM) at the American Society of Health-System Pharmacists on December 7th 3Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 1Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 2Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 1Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 2Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 3Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 4Bones May Suffer From Green Tea Consumption 57484 1
...raging Response in CF Patients - Results Validate..., BETHESDA, Md., March 27 The Cystic Fibrosis Fo... in development that targets a,basic defect in CF,...linical trial for patients who carry the G551D mut... Pharmaceuticals Incorporated., Patients who took...
...epligen Corporation,(Nasdaq: RGEN ) announced tod...al trial to evaluate the use of RG1068, synthetic ...eatic duct structures by magnetic resonance,imagin...eline-controlled,single dose study in which approx...I followed by a secretin-enhanced MRI of the pancr...
Other Medicine Technology:Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 2Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 3Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 2Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 3Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 4
(Date:11/30/2009).../ -- Physicians at Beth Israel Deaconess Medical C...y demonstrating the potential for automated analys...OR Analyzer System® to assist in rapidly ruli...ncy department (ED ) patients with chest pain. The...e of cCTA has potential to significantly reduce un...
(Date:11/30/2009)... response to a "cocaine-cues" video, active cocain...ity in brain regions linked to drug craving, accor...gy,s Brookhaven National Laboratory. The results, ...e , suggest that clinical interventions designed t... cocaine abusers stop using drugs and avoid relaps...
(Date:11/30/2009)...ore often than younger people, study finds, , ... people who are problem drinkers consume more alco...finds, possibly because they need more alcohol to ...y released this month, people dependent on alcohol... a week, on average. By contrast, younger alcoholi...
(Date:11/30/2009)...30 Baxa Corporation is sponsoring ...re of safety" means in today,s pharmacy environmen...a Culture of Safety in Pharmacy ," features a pane...experiences with culture of safety, what it takes ...ole of technology in enabling or inhibiting safe p...
(Date:11/30/2009)...swire/ -- A new study has found that 27% of Medica...ustomers have a current intention to shop for and ...re is up from 20% in 2008. Over the past four yea...eading indicator of actual switching patterns. W...tually will leave their current insurer for anothe...
Breaking Medicine News(10 mins):Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 2Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 3Health News:Brain scan study shows cocaine abusers can control cravings 2Health News:Brain scan study shows cocaine abusers can control cravings 3Health News:Binge Drinking Not Just a Rite of the Young 2Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 2Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 3Health News:More Seniors Considering Health Insurance Switch 2
...RNewswire-FirstCall/ - IMRIS Inc. (TSX: IM) ("IMRI...iversity Huashan Hospital in Shanghai, China has s... department. Huashan Hospital will be the first in...dure without moving the patient. The project inclu...
...THAT ASTHMA PATIENTS WHO STOP USING ASTHMA CONTROL... , WASHINGTON , April 15 A new nationwide tel...ost asthma patients know the risks of "uncontrolle...s are not present. Data from The Asthma G.A.P. ...
...andards for First National Measures of Hospital Ef...art Angioplasty, and Pneumonia , , Detailed Hospi...group.org/cp , , WASHINGTON, April 15 Though it...ospitals still have failed to implement standards ...
... 15 Baptist Memorial Health Care Corp. em... phase of the "Our House is Your House" capital ca...emmons Wilson Family Center for Good Grief as they...g out to their colleagues to make donations. , , ...
...d NEW YORK, April 15 HLTH Corporation (Nasdaq: ... WebMD Health Corp. (Nasdaq: WBMD ), today annou...cial results for the three months ended March 31, ...ults. , , Investors can access the call via web...
...f endoscopic ultrasound (EUS) examination is its l... lesion. The differential diagnosis between benign...sses based on the EUS appearance is difficult and ...chnique that can be applied during ultrasound (US)...
Other Medicine News:Health News:National Survey Reveals Gap in 'Uncontrolled Asthma' Knowledge - Putting Asthma Patients at Risk for Serious Health Consequences 2Health News:National Survey Reveals Gap in 'Uncontrolled Asthma' Knowledge - Putting Asthma Patients at Risk for Serious Health Consequences 3Health News:National Survey Reveals Gap in 'Uncontrolled Asthma' Knowledge - Putting Asthma Patients at Risk for Serious Health Consequences 4Health News:Leapfrog Group Hospital Survey Finds Majority of Hospitals Fail to Meet Important Quality Standards 2Health News:Leapfrog Group Hospital Survey Finds Majority of Hospitals Fail to Meet Important Quality Standards 3Health News:Leapfrog Group Hospital Survey Finds Majority of Hospitals Fail to Meet Important Quality Standards 4Health News:Baptist Colleagues Raise $1 Million for Baptist Trinity Hospice House and Kemmons Wilson Family Center for Good Grief 2Health News:HLTH and WebMD Announce First Quarter Earnings Release Date and Conference Call 2Health News:Can EUS elastography help distinguish benign from malignant tissue? 2
Hunkeler IOL Manipulator
Guimaraes ICL Manipulator
Lester IOL Manipulator
...scopes are individually adjusted for perfect focus...s, along with Keeler's wide angle light beam and i... pupil size, you will see the clearest and largest...longer life battery and fast charge capability. Wi...
Medicine Products: